MedTrace Logo

A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes

NCT00964418 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-01-20

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this clinical trial is to investigate the blood glucose lowering effect of NN1250 (insulin degludec) in young and elderly subjects with type 1 diabetes.

Conditions

Interventions

DRUG

insulin degludec

0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days

DRUG

insulin glargine

0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00964418 on ClinicalTrials.gov